-
1
-
-
64649104158
-
Banting Lecture. From the triumvirate to the ominous octet: A new paradigm for the treatment of type 2 diabetes mellitus
-
DeFronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009; 58: 773-795.
-
(2009)
Diabetes
, vol.58
, pp. 773-795
-
-
DeFronzo, R.A.1
-
2
-
-
0032511583
-
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
-
UK Prospective Diabetes Study (UKPDS) Group
-
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
-
(1998)
Lancet
, vol.352
, pp. 837-853
-
-
-
3
-
-
0032983666
-
Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49)
-
UK Prospective Diabetes Study (UKPDS) Group
-
Turner RC, Cull CA, Frighi V, Holman RR and UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999; 281: 2005-2012.
-
(1999)
JAMA
, vol.281
, pp. 2005-2012
-
-
Turner, R.C.1
Cull, C.A.2
Frighi, V.3
Holman, R.R.4
-
4
-
-
33845405222
-
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
-
DOI 10.1056/NEJMoa066224
-
Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-2443. (Pubitemid 44903747)
-
(2006)
New England Journal of Medicine
, vol.355
, Issue.23
, pp. 2427-2443
-
-
Kahn, S.E.1
Haffner, S.M.2
Heise, M.A.3
Herman, W.H.4
Holman, R.R.5
Jones, N.P.6
Kravitz, B.G.7
Lachin, J.M.8
O'Neill, M.C.9
Zinman, B.10
Viberti, G.11
-
5
-
-
33745006572
-
1c following successful initial metformin therapy
-
Nichols GA, Alexander CM, Girman CJ, Kamal-Bahl SJ and Brown JB. Treatment escalation and rise in HbA1c following successful initial metformin therapy. Diabetes Care 2006; 29: 504-509. (Pubitemid 44115344)
-
(2006)
Diabetes Care
, vol.29
, Issue.3
, pp. 504-509
-
-
Nichols, G.A.1
Alexander, C.M.2
Girman, C.J.3
Kamal-Bahl, S.J.4
Brown, J.B.5
-
6
-
-
33644874319
-
Earlier intervention in type 2 diabetes: The case for achieving early and sustained glycaemic control
-
DOI 10.1111/j.1742-1241.2005.00675.x
-
Bailey CJ, Del Prato S, Eddy D and Zinman B. Earlier intervention in type 2 diabetes: the case for achieving early and sustained glycaemic control. Int J Clin Pract 2005; 59: 1309-1316. (Pubitemid 43904502)
-
(2005)
International Journal of Clinical Practice
, vol.59
, Issue.11
, pp. 1309-1316
-
-
Bailey, C.J.1
Del, P.S.2
Eddy, D.3
Zinman, B.4
Albetti, G.5
Aschner, P.P.6
Blonde, L.7
Felton, A.-M.8
Goldstein, B.9
Gomis, R.10
Horton, E.11
LaSalle, J.J.12
Lee, H.-K.13
Leiter, L.14
Matthaei, S.15
McGill, M.16
Munro, N.17
Nesto, R.18
Zimmet, P.19
-
7
-
-
64749100501
-
Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
-
Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R and Zinman B. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193-203.
-
(2009)
Diabetes Care
, vol.32
, pp. 193-203
-
-
Nathan, D.M.1
Buse, J.B.2
Davidson, M.B.3
Ferrannini, E.4
Holman, R.R.5
Sherwin, R.6
Zinman, B.7
-
8
-
-
75549091263
-
Statement by an American Association of Clinical Endocrinologists/ American College of Endocrinology Consensus Panel on type 2 diabetes mellitus: An algorithm for glycemic control
-
Rodbard HW, Jellinger PS, Davidson JA, Einhorn D, Garber AJ, Grunberger G, et al. Statement by an American Association of Clinical Endocrinologists/ American College of Endocrinology Consensus Panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocrine Practice 2009; 15: 541-559.
-
(2009)
Endocrine Practice
, vol.15
, pp. 541-559
-
-
Rodbard, H.W.1
Jellinger, P.S.2
Davidson, J.A.3
Einhorn, D.4
Garber, A.J.5
Grunberger, G.6
-
9
-
-
22744449063
-
Discovery and preclinical profile of saxagliptin (BMS-477118): A highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
-
DOI 10.1021/jm050261p
-
Augeri DJ, Robl JA, Betebenner DA, Magnin DR, Khanna A, Robertson JG, et al. Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2005; 48: 5025-5037. (Pubitemid 41033142)
-
(2005)
Journal of Medicinal Chemistry
, vol.48
, Issue.15
, pp. 5025-5037
-
-
Augeri, D.J.1
Robl, J.A.2
Betebenner, D.A.3
Magnin, D.R.4
Khanna, A.5
Robertson, J.G.6
Wang, A.7
Simpkins, L.M.8
Taunk, P.9
Huang, Q.10
Han, S.-P.11
Abboa-Offei, B.12
Cap, M.13
Xin, L.14
Tao, L.15
Tozzo, E.16
Welzel, G.E.17
Egan, D.M.18
Marcinkeviciene, J.19
Chang, S.Y.20
Biller, S.A.21
Kirby, M.S.22
Parker, R.A.23
Hamann, L.G.24
more..
-
10
-
-
67449103220
-
Redefining the role of thiazolidinediones in the management of type 2 diabetes
-
Barnett AH. Redefining the role of thiazolidinediones in the management of type 2 diabetes. Vasc Health Risk Manag 2009; 5: 141-151.
-
(2009)
Vasc Health Risk Manag
, vol.5
, pp. 141-151
-
-
Barnett, A.H.1
-
11
-
-
74549198914
-
-
Bristol-Myers Squibb Company AstraZeneca Pharmaceuticals LP. Princeton, NJ/Wilmington, DE, Bristol-Myers Squibb Company/AstraZeneca Pharmaceuticals LP
-
Bristol-Myers Squibb Company AstraZeneca Pharmaceuticals LP. Onglyza [package insert]. Princeton, NJ/Wilmington, DE, Bristol-Myers Squibb Company/AstraZeneca Pharmaceuticals LP, 2009.
-
(2009)
Onglyza [Package Insert]
-
-
-
12
-
-
70549096922
-
Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition
-
Kirby M, Ming Tse Yu D, O'Connor S and Gorrell M. Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition. Clin Sci 2010; 118: 31-41.
-
(2010)
Clin Sci
, vol.118
, pp. 31-41
-
-
Kirby, M.1
Ming Tse Yu, D.2
O'Connor, S.3
Gorrell, M.4
-
13
-
-
77951758117
-
Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus
-
Neumiller JJ, Wood L and Campbell RK. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus. Pharmacotherapy 2010; 30: 463-484.
-
(2010)
Pharmacotherapy
, vol.30
, pp. 463-484
-
-
Neumiller, J.J.1
Wood, L.2
Campbell, R.K.3
-
14
-
-
77951702763
-
Safety, tolerability, pharmacokinetics and pharmacodynamics of once-daily oral doses of saxagliptin for 2 weeks in type 2 diabetic and healthy subjects
-
abstract
-
Boulton D and Geraldes M. Safety, tolerability, pharmacokinetics and pharmacodynamics of once-daily oral doses of saxagliptin for 2 weeks in type 2 diabetic and healthy subjects. [abstract]. Diabetes 2007; 56(suppl 1): 606P.
-
(2007)
Diabetes
, vol.56
, Issue.SUPPL. 1
, pp. 606
-
-
Boulton, D.1
Geraldes, M.2
-
15
-
-
73149084956
-
Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone
-
for the CV181- 013 investigators.
-
Hollander P, Li J, Allen E, Chen R and for the CV181- 013 investigators. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. J Clin Endocrinol Metab 2009; 94: 4810-4819.
-
(2009)
J Clin Endocrinol Metab
, vol.94
, pp. 4810-4819
-
-
Hollander, P.1
Li, J.2
Allen, E.3
Chen, R.4
-
16
-
-
70349314675
-
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled study
-
Pratley RE, Reusch JE, Fleck PR, Wilson CA and Mekki Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Curr Med Res Opin 2009; 25: 2361-2371.
-
(2009)
Curr Med Res Opin
, vol.25
, pp. 2361-2371
-
-
Pratley, R.E.1
Reusch, J.E.2
Fleck, P.R.3
Wilson, C.A.4
Mekki, Q.5
-
17
-
-
33751557143
-
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study
-
DOI 10.1016/j.clinthera.2006.10.007, PII S0149291806002475
-
Rosenstock J, Brazg R, Andryuk PJ, Lu K and Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2006; 28: 1556-1568. (Pubitemid 44841980)
-
(2006)
Clinical Therapeutics
, vol.28
, Issue.10
, pp. 1556-1568
-
-
Rosenstock, J.1
Brazg, R.2
Andryuk, P.J.3
Lu, K.4
Stein, P.5
-
18
-
-
34250212715
-
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
-
Nissen SE and Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-2471. (Pubitemid 46919772)
-
(2007)
New England Journal of Medicine
, vol.356
, Issue.24
, pp. 2457-2471
-
-
Nissen, S.E.1
Wolski, K.2
-
19
-
-
76349117322
-
Once-daily saxagliptin added to metformin provides sustained glycemic control and is well tolerated over 102 weeks in patients with type 2 diabetes
-
DeFronzo R, Hissa MN, Garber AJ, Gross JL, Duan RY, Ravichandran S, et al. Once-daily saxagliptin added to metformin provides sustained glycemic control and is well tolerated over 102 weeks in patients with type 2 diabetes. Diabetes 58(suppl 1):, 547-P.
-
Diabetes
, vol.58
, Issue.SUPPL. 1
-
-
DeFronzo, R.1
Hissa, M.N.2
Garber, A.J.3
Gross, J.L.4
Duan, R.Y.5
Ravichandran, S.6
-
20
-
-
21344451651
-
Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes
-
DOI 10.1007/s00125-005-1751-1
-
Charbonnel B, Schernthaner G, Brunetti P, Matthews DR, Urquhart R, Tan MH, et al. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia 2005; 48: 1093-1104. (Pubitemid 40909644)
-
(2005)
Diabetologia
, vol.48
, Issue.6
, pp. 1093-1104
-
-
Charbonnel, B.1
Schernthaner, G.2
Brunetti, P.3
Matthews, D.R.4
Urquhart, R.5
Tan, M.H.6
Hanefeld, M.7
-
21
-
-
36448968168
-
Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus
-
Hermansen K and Mortensen LS. Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus. Drug Saf 2007; 30: 1127-1142. (Pubitemid 350172854)
-
(2007)
Drug Safety
, vol.30
, Issue.12
, pp. 1127-1142
-
-
Hermansen, K.1
Mortensen, L.S.2
-
22
-
-
34447267513
-
Efficacy and safety of incretin therapy in type 2 diabetes: Systematic review and meta-analysis
-
DOI 10.1001/jama.298.2.194
-
Amori RE, Lau J and Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007; 298: 194-206. (Pubitemid 47057766)
-
(2007)
Journal of the American Medical Association
, vol.298
, Issue.2
, pp. 194-206
-
-
Amori, R.E.1
Lau, J.2
Pittas, A.G.3
-
23
-
-
77953108350
-
A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes
-
Frederich R, Alexander JH, Fiedorek FT, Donovan M, Berglind N, Harris S, et al. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med 2010; 122: 16-27.
-
(2010)
Postgrad Med
, vol.122
, pp. 16-27
-
-
Frederich, R.1
Alexander, J.H.2
Fiedorek, F.T.3
Donovan, M.4
Berglind, N.5
Harris, S.6
-
24
-
-
13644263258
-
Oral antidiabetic agents: Current role in type 2 diabetes mellitus
-
DOI 10.2165/00003495-200565030-00005
-
Krentz AJ and Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs 2005; 65: 385-411. (Pubitemid 40227460)
-
(2005)
Drugs
, vol.65
, Issue.3
, pp. 385-411
-
-
Krentz, A.J.1
Bailey, C.J.2
-
25
-
-
0035408779
-
A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes
-
Raskin P, Rendell M, Riddle MC, Dole JF, Freed MI and Rosenstock J. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care 2001; 24: 1226-1232. (Pubitemid 33716403)
-
(2001)
Diabetes Care
, vol.24
, Issue.7
, pp. 1226-1232
-
-
Raskin, P.1
Rendell, M.2
Riddle, M.C.3
Dole, J.F.4
Freed, M.I.5
Rosenstock, J.6
|